Daiichi Sankyo

News

NICE turns down Enhertu in “devastating” move, says charity

AstraZeneca and Daiichi Sankyo’s Enhertu should not be made available via the NHS for HER2-low metastatic or unresectable breast cancer after chemotherapy, according to pr

News

AZ, Daiichi Sankyo cue up TROP2 drug filing in breast cancer

Armed with the first phase 3 data for their TROP2-targeting antibody-drug conjugate (ADC) datopotamab deruxtecan as a second-line treatment for breast cancer, AstraZeneca

News

WCLC: Data back first-line use of Gilead, AZ/Daiichi TROP2s

AstraZeneca/Daiichi Sankyo and Gilead Sciences have reported preliminary results of studies that suggest their TROP2-targeted antibody-drug conjugates (ADCs) could have a

News

WCLC: Daiichi Sankyo HER3 ADC readout sets up filings

A mid-stage trial of Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan has hit the mark and will form the basis of regulatory filings for the d

Oncology

Healthcare is a team sport: Tackling cancer inequalities in ...

Throughout history, great scientific advancements have been made through collaboration.

News

Enhertu shows survival boost in HER2+ solid tumours

AstraZeneca and Daiichi Sankyo's chances of getting approval for Enhertu as a therapy for all HER2-positive tumours – regardless of their location in the body – have just

NICE turns down Enhertu in “devastating” move, says charity

AZ, Daiichi Sankyo cue up TROP2 drug filing in breast cancer

WCLC: Data back first-line use of Gilead, AZ/Daiichi TROP2s

WCLC: Daiichi Sankyo HER3 ADC readout sets up filings

Healthcare is a team sport: Tackling cancer inequalities in ...

Enhertu shows survival boost in HER2+ solid tumours

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Daiichi Sankyo

Editor's Picks